- Home
- VRNT vs ZYME Comparison
VRNT vs ZYME Comparison
Compare VRNT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNT
- ZYME
- Stock Information
- Founded
- VRNT 1994
- ZYME 2003
- Country
- VRNT United States
- ZYME United States
- Employees
- VRNT N/A
- ZYME N/A
- Industry
- VRNT EDP Services
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- VRNT Technology
- ZYME Health Care
- Exchange
- VRNT Nasdaq
- ZYME Nasdaq
- Market Cap
- VRNT 1.1B
- ZYME 867.6M
- IPO Year
- VRNT N/A
- ZYME 2017
- Fundamental
- Price
- VRNT $16.67
- ZYME $12.48
- Analyst Decision
- VRNT Buy
- ZYME Buy
- Analyst Count
- VRNT 6
- ZYME 7
- Target Price
- VRNT $30.33
- ZYME $19.50
- AVG Volume (30 Days)
- VRNT 1.4M
- ZYME 442.6K
- Earning Date
- VRNT 06-04-2025
- ZYME 07-31-2025
- Dividend Yield
- VRNT N/A
- ZYME N/A
- EPS Growth
- VRNT 79.53
- ZYME N/A
- EPS
- VRNT 0.84
- ZYME N/A
- Revenue
- VRNT $896,006,000.00
- ZYME $93,384,000.00
- Revenue This Year
- VRNT $7.65
- ZYME $44.71
- Revenue Next Year
- VRNT $5.54
- ZYME $34.57
- P/E Ratio
- VRNT $19.76
- ZYME N/A
- Revenue Growth
- VRNT N/A
- ZYME 85.05
- 52 Week Low
- VRNT $14.15
- ZYME $8.21
- 52 Week High
- VRNT $37.31
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- VRNT 39.96
- ZYME 53.22
- Support Level
- VRNT $16.23
- ZYME $12.33
- Resistance Level
- VRNT $19.65
- ZYME $13.44
- Average True Range (ATR)
- VRNT 0.87
- ZYME 0.57
- MACD
- VRNT -0.20
- ZYME 0.02
- Stochastic Oscillator
- VRNT 7.57
- ZYME 54.85
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries, helps brands provide Boundless customer experience (CX) automation. AI offers a solution, and that's where Verint comes in. It empowers brands with groundbreaking AI via a next-gen open platform. Its Verint Open Platform helps organizations increase CX automation to achieve their strategic objectives and realize ROI. Geographically, it derives a majority of its revenue from the United States.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.